Chengdu Fanoxi Biopharmaceutical Technology

Chengdu Fanoxi Biopharmaceutical Technology is a clinical-stage biotechnology company focused on the discovery and development of next-generation small molecule drugs for oncology. Headquartered in Chengdu, China, the company utilizes a proprietary covalent drug discovery platform to address challenging and previously undruggable targets within the MAPK signaling pathway. Its lead program, FX-001, is a potent and selective KRAS G12C inhibitor currently undergoing Phase 1 clinical trials for patients with advanced solid tumors. Beyond its lead candidate, Fanoxi is advancing a pipeline of inhibitors targeting SOS1 and SHP2 to provide comprehensive treatment options and overcome drug resistance. The company is backed by prominent venture capital firms and aims to deliver precision medicines to cancer patients globally.